MATERNAL EXPOSURE VIA PARTNER DURING PREGNANCY

MATERNAL EXPOSURE VIA PARTNER DURING PREGNANCY was reported 64 times

MATERNAL EXPOSURE VIA PARTNER DURING PREGNANCY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Thyroid Hormone Receptor beta Agonist [EPC] 5 0.0022
1 Interleukin-17 Receptor A Antagonist [EPC] 2 0.0010
2 CD22-directed Immunoconjugate [EPC] 2 0.0007
3 Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] 3 0.0003
4 Interleukin-17A Antagonist [EPC] 6 0.0002
5 Asparagine-specific Enzyme [EPC] 1 0.0001
6 Programmed Death Receptor-1 Blocking Antibody [EPC] 6 0.0001
7 Antimetabolite Immunosuppressant [EPC] 1 0.0000
8 Epidermal Growth Factor Receptor Antagonist [EPC] 2 0.0000
9 Nucleoside Analog Antiviral [EPC] 2 0.0000
10 Vascular Endothelial Growth Factor Inhibitor [EPC] 3 0.0000
11 CD20-directed Cytolytic Antibody [EPC] 5 0.0000
12 Histamine-1 Receptor Antagonist [EPC] 1 0.0000
13 Integrin Receptor Antagonist [EPC] 1 0.0000
14 Nucleoside Metabolic Inhibitor [EPC] 3 0.0000
15 5-alpha Reductase Inhibitor [EPC] 1 0.0000
16 Platinum-based Drug [EPC] 2 0.0000
17 Xanthine Oxidase Inhibitor [EPC] 1 0.0000
18 Folate Analog Metabolic Inhibitor [EPC] 2 0.0000
19 Atypical Antipsychotic [EPC] 2 0.0000
20 Alkylating Drug [EPC] 1 0.0000
21 Kinase Inhibitor [EPC] 2 0.0000
22 Vitamin D [EPC] 1 0.0000
23 Angiotensin 2 Receptor Blocker [EPC] 1 0.0000
24 Corticosteroid [EPC] 4 0.0000
25 Vitamin B12 [EPC] 1 0.0000
26 Dihydropyridine Calcium Channel Blocker [EPC] 1 0.0000
27 Vitamin C [EPC] 1 0.0000
28 GLP-1 Receptor Agonist [EPC] 1 0.0000
29 Tumor Necrosis Factor Blocker [EPC] 2 0.0000
30 Interleukin-4 Receptor alpha Antagonist [EPC] 1 0.0000
31 Thalidomide Analog [EPC] 1 0.0000
32 Proton Pump Inhibitor [EPC] 1 0.0000